Mcp (Metoclopramide Hydrochloride)

Metoclopramide blocks dopamine D2 receptors in the brain’s chemoreceptor trigger zone and in the gastrointestinal tract. This action reduces the vomiting reflex, speeds up stomach emptying, and strengthens the lower oesophageal sphincter, helping to control reflux and improve digestive transit.

The appropriate dose of Mcp is determined by the prescribing healthcare professional based on the patient’s condition, age, renal function and other clinical factors. Dosage regimens are individualized and should follow the prescriber’s instructions and local labeling.

Safety data for metoclopramide in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare provider after careful assessment.

To order Mcp, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoclopramide differs from many antiemetics by acting as a dopamine antagonist and a gastroprokinetic agent, whereas drugs like ondansetron target serotonin receptors. This dual action makes metoclopramide useful for both nausea control and enhancing gastric motility, but it also carries a distinct side‑effect profile.

Mcp should be stored at room temperature, below 25 °C. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure the container is tightly closed to maintain product stability.

Mcp is taken orally, usually with a glass of water. The tablet should be swallowed whole and not chewed or crushed unless specifically instructed by a healthcare professional. Administration timing (e.g., before meals) depends on the therapeutic indication and prescriber guidance.

Serious risks include extrapyramidal reactions such as dystonia or tardive dyskinesia, neuroleptic malignant syndrome, severe allergic responses, and potential depression or suicidal thoughts. Patients should be monitored closely for any of these symptoms, and treatment should be stopped if they occur.

Metoclopramide is contraindicated in individuals with known hypersensitivity to the drug, those with pheochromocytoma, and patients with a history of severe extrapyramidal disorders. Caution is also advised for patients with renal impairment, gastrointestinal obstruction or perforation, and for the elderly.